1186633-78-2

Basic information

• Product Name: 5-(4-(5-(4-(4-cyclohexylbenzyloxy)benzylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)-1,1-dioxo-1λ6-[1,2,5]thiadiazolidin-3-one
• Synonyms: 5-(4-(5-(4-(4-cyclohexylbenzyloxy)benzylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)-1,1-dioxo-1λ6-[1,2,5]thiadiazolidin-3-one
• CAS NO: 1186633-78-2
• Molecular Weight: 616.762
• Mol File: 1186633-78-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-(4-(5-(4-(4-cyclohexylbenzyloxy)benzylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)-1,1-dioxo-1λ6-[1,2,5]thiadiazolidin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-(5-(4-(4-cyclohexylbenzyloxy)benzylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)-1,1-dioxo-1λ6-[1,2,5]thiadiazolidin-3-one(1186633-78-2)
• EPA Substance Registry System: 5-(4-(5-(4-(4-cyclohexylbenzyloxy)benzylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)phenyl)-1,1-dioxo-1λ6-[1,2,5]thiadiazolidin-3-one(1186633-78-2)

Safety Data

• Hazardous Substances Data: 1186633-78-2(Hazardous Substances Data)

Upstream product

• 1186634-26-3 4-(4-cyclohexylbenzyloxy)benzaldehyde 
• 1186634-25-2 5-(4-(3-methyl-4-oxo-1,3-thiazolidin-2-ylideneamino)phenyl)-1,1-dioxo-1λ6-[1,2,5]thiadiazolidin-3-one 
• 63500-84-5 3-methyl-2-(4-nitro-phenylimino)-thiazolidin-4-one 
• 4463-31-4 4-cyclohexylbenzyl chloride 
• 20029-52-1 4-cyclohexylbenzoic acid 
• 1186634-21-8 2-(4-aminophenylimino)-3-methylthiazolidin-4-one 
• 1186634-22-9 (4-(3-methyl-4-oxothiazolidin-2-ylideneamino)phenylamino)acetic acid ethyl ester 
• 1186634-24-1 ((4-((3-methyl-4-oxo-1,3-thiazolidin-2-ylidene)amino)phenyl)(sulfamoyl)amino)acetic acid ethyl ester 
• 16361-69-6 1-(4-nitrophenyl)-3-methyl-thiourea 
• 208259-47-6 4-cyclohexylphenylmethyl alcohol 
• 959141-01-6 4-cyclohexyl-benzoic acid ethyl ester 

Relevant articles and documents

NOVEL PROTEIN TYROSINE PHOSPHATASE - IB INHIBITORS

The present invention relates to the novel compounds of the general formula (I), wherein the symbols are same as described in specification, their pharmaceutically acceptable salts, their tautomeric forms, their stereoisomers, pharmaceutical compositions containing them, to process and intermediates for the preparation of the above said compounds, having the utility of these compounds in medicine and to methods for their therapeutic use, and their use in the treatment of diabetes and related diseases.